Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Updating the Adherence–Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women
Peter L. Anderson, Mark A. Marzinke, David V. Glidden
Clinical Infectious Diseases (2023) Vol. 76, Iss. 10, pp. 1850-1853
Closed Access | Times Cited: 23

Showing 23 citing articles:

HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women
Jeanne Marrazzo, Tao Li, Marissa Becker, et al.
JAMA (2024) Vol. 331, Iss. 11, pp. 930-930
Open Access | Times Cited: 27
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel
Rajesh T. Gandhi, Raphael J. Landovitz, Paul E. Sax, et al.
JAMA (2024)
Closed Access | Times Cited: 13
Event-driven PrEP beyond cisgender men who have sex with men
Whitney C. Irie, Melanie R. Nicol, Meredith E. Clement, et al.
The Lancet HIV (2025)
Closed Access | Times Cited: 1
Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women
Lanxin Zhang, Sara Iannuzzi, Ayyappa Chaturvedula, et al.
Nature Medicine (2023) Vol. 29, Iss. 11, pp. 2753-2762
Open Access | Times Cited: 14
Intracellular dried blood spot metabolite concentrations for assessing antiretroviral adherence and HIV progression
Julie B. Dumond
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2025)
Closed Access
Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV — CDC Recommendations, United States, 2025
Mary R. Tanner, Jesse O’Shea, Katrina Byrd, et al.
MMWR Recommendations and Reports (2025) Vol. 74, Iss. 1, pp. 1-56
Open Access
Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence
Mia Moore, Sarah Stansfield, Deborah Donnell, et al.
Nature Medicine (2023) Vol. 29, Iss. 11, pp. 2748-2752
Open Access | Times Cited: 9
Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With Human Immunodeficiency Virus Receiving Tenofovir Alafenamide and Emtricitabine–Based Antiretroviral Therapy (QUANTI-TAF)
Ryan P. Coyle, Mary Morrow, Sarah Mann, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 5, pp. 1233-1241
Closed Access | Times Cited: 3
HIV Pre-Exposure Prophylaxis
Geoffroy Liégeon, Constance Delaugerre, Jean‐Michel Molina
Infectious Disease Clinics of North America (2024) Vol. 38, Iss. 3, pp. 453-474
Closed Access | Times Cited: 3
Modeling of HIV‐1 prophylactic efficacy and toxicity with islatravir shows non‐superiority for oral dosing, but promise as a subcutaneous implant
Hee‐yeong Kim, Lanxin Zhang, Craig W. Hendrix, et al.
CPT Pharmacometrics & Systems Pharmacology (2024) Vol. 13, Iss. 10, pp. 1693-1706
Open Access | Times Cited: 2
Shifting the Narrative of Preexposure Prophylaxis Adherence Counseling for Cisgender Women
Anandi N. Sheth, Florence Momplaisir, Julie B. Dumond
JAMA (2024) Vol. 331, Iss. 11, pp. 912-912
Open Access | Times Cited: 1
Establishing adherence–concentration–efficacy thresholds of TDF–FTC pre-exposure prophylaxis for HIV prevention in African women: a protocol for the Women TDF–FTC Benchmark Study
Linxuan Wu, M. Saina, Clare Brown, et al.
Frontiers in Reproductive Health (2024) Vol. 6
Open Access | Times Cited: 1
Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review
Linxuan Wu, Xin Niu, Marisa Kaitlin Brunelli, et al.
Current HIV/AIDS Reports (2024) Vol. 21, Iss. 5, pp. 264-281
Closed Access | Times Cited: 1
High recent PrEP adherence with point‐of‐care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohort
Brenda Gati Mirembe, Deborah Donnell, Meighan Krows, et al.
Journal of the International AIDS Society (2024) Vol. 27, Iss. 12
Open Access | Times Cited: 1
A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention
Erick Leung, Mackenzie L. Cottrell, Craig Sykes, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 12, pp. 1922-1930
Open Access | Times Cited: 1
An update on long-acting agents in HIV therapy
Laura Pezzati, G Canavesi, Stefano Rusconi
Future Virology (2023) Vol. 18, Iss. 13, pp. 881-893
Closed Access | Times Cited: 1
Modeling of HIV-1 prophylactic efficacy and toxicity with islatravir shows non-superiority for oral dosing, but promise as a subdermal implant
H. Y. Kim, Lanxin Zhang, Craig W. Hendrix, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Updated guidelines on HIV post‐exposure prophylaxis: continued efforts towards increased accessibility
Lao‐Tzu Allan‐Blitz, Kenneth H. Mayer
Journal of the International AIDS Society (2024) Vol. 27, Iss. 11
Open Access
Adherence measurement considerations for oral antiretroviral medications
Corwin Coppinger, Peter L. Anderson
Journal of the International AIDS Society (2024) Vol. 27, Iss. 12
Open Access
Is Lenacapavir Needed for Individuals Adherent to Daily Oral PrEP?
Xin Niu, Paul K. Drain
JAMA (2024)
Closed Access
December 1st, World AIDS Day
T. López, Elena López
Latin American Journal of Clinical Sciences and Medical Technology (2024) Vol. 6, Iss. 1, pp. 352-353
Closed Access
Reply to Niu and Drain
Peter L. Anderson, Mark A. Marzinke, David V. Glidden
Clinical Infectious Diseases (2023) Vol. 78, Iss. 3, pp. 802-803
Closed Access
Is Higher Adherence Required for Women Using Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis?
Xin Niu, Paul K. Drain
Clinical Infectious Diseases (2023) Vol. 78, Iss. 3, pp. 801-802
Closed Access
Page 1

Scroll to top